Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases, with a presentation scheduled at the J.P. Morgan Healthcare Conference [1]. Company Overview - Maze Therapeutics utilizes human genetics to create novel small molecule precision medicines targeting kidney and metabolic diseases, including obesity [3]. - The company operates its Compass™ platform to identify genetically validated targets, integrating variant discovery and functionalization to advance small molecule programs with first- or best-in-class potential [3]. - The pipeline includes MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease, and MZE782, a SLC6A19 inhibitor advancing to Phase 2 for phenylketonuria and chronic kidney disease [3]. - Maze Therapeutics is headquartered in South San Francisco [3].